Episode 21: Glass Box Wins - What Pharma Actually Trusts in AI

In this episode of From Models to Medicine, we sit down with Lavanya Anandan, Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering versus where it's mostly promise. She makes a sharp case that the companies winning in AI-bio aren't necessarily the ones with the best models, and the reason why might surprise you.We get into what big pharma wants from an AI partner, why women's health data scarcity is quietly producing some of the most rigorous AI in biology, and what an unexpected finding in mRNA research tells us about where this whole field might be heading. Articles mentioned in show: https://endpoints.news/can-ai-do-scientific-research-billions-chase-hopes-of-superintelligence/Maven course: https://maven.com/kamithinktank/ai-literacy-for-life-sciences-healthcare